Hepatocellular carcinoma is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx), an angiogenesis inhibitor, was the only drug approved for advanced patients until the 2017 / 2018 approvals of Stivarga (Bayer HealthCare), Opdivo (Bristol Myers Squibb / Ono Pharmaceutical), Keytruda (Merck & Co.), Lenvima (Eisai / Merck & Co.), Cabometyx (Exelixis), Cyramza (Eli Lilly), and the 2020 approvals of Tecentriq plus Avastin (Roche / Genentech) and Opdivo and Yervoy (Bristol Myers Squibb / Ono Pharmaceutical). The late-phase drug development pipeline, predominantly focused on the advanced-stage hepatocellular carcinoma segment, encompasses a diverse range of mechanisms of action. The hepatocellular carcinoma market is mostly driven by approvals of premium-priced immune checkpoint inhibitors and the expected uptake of combination regimens. Because the hepatocellular carcinoma market is largely untapped, the developer of an efficacious therapy could reap high commercial rewards.

Questions Answered

  • What is the current treatment landscape for hepatocellular carcinoma, and what clinical needs remain unfulfilled?
  • Which drug classes are in the late-phase development pipeline, and which agents are the most promising?
  • How is the drug-treatable hepatocellular carcinoma population defined, and how will drug-treatment rates change over time?
  • Which emerging therapies do we forecast to enter each of the hepatocellular carcinoma market segments?
  • What uptake and sales are these therapies anticipated to secure?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 19 country-specific interviews with thought leaders (medical oncologists).

Key companies: Bayer HealthCare / Amgen / Onyx, Bristol Myers Squibb / Ono Pharmaceutical, Merck & Co., Eisai, Exelixis / Ipsen, Eli Lilly, Roche / Genentech.

Key drugs: Nexavar, Stivarga, Cabometyx, Cyramza, Avastin, Tecentriq, Opdivo, Yervoy, Lenvima, Keytruda.

Population segments in market forecast: Early-stage, first-line intermediate-stage, second-line intermediate-stage, first-line advanced-stage, and second-line advanced-stage hepatocellular carcinoma.

Emerging therapies: Phase III/PR: 5 drugs; Phase II: 18 drugs; coverage of select preclinical and Phase I products.

Table of contents

  • Hepatocellular Carcinoma - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Ananya Sadhu, Ph.D; Oliver Blandy

Ananya Sadhu, Ph.D., is an analyst with the oncology team at Decision Resources Group with expertise in multiple oncology indications including pancreatic cancer.

Prior to joining Decision Resources Group, Dr. Ananya Sadhu was a postdoctoral fellow at National Centre of Biological Sciences, Bangalore, where she studied the role of chromatin architecture in regulating gene expression in breast cancer. Ananya holds a Ph.D. in Molecular Biology from National Institute of Immunology, New Delhi. She also worked as a Scientific Officer with Arvind Remedies Ltd., a pharmaceutical company, where she coordinated various stages of non-clinical / clinical research activities for drug development of a U.S. patented polyherbal formulation.

Oliver Blandy, BSc PGCE MSc, joined Decision Resources Group (DRG) as an Associate Epidemiologist in 2017. He focuses on the epidemiology of cancer.

Oliver holds an MSc from the University of Bristol where he specialized in Nutrition, Physical Activity and Public Health. He also holds a BSc in Chemistry and has a Post Graduate Certificate in Education (PGCE), both from the University of Bristol and taught general science and Advanced Chemistry in high school for two years.

Before joining the team at DRG, Oliver worked as a Research Assistant for Imperial College London where he was the lead for several studies within an NIRH funded research group that investigated healthcare associated infections and antimicrobial resistance.

Related Reports

Hepatocellular Carcinoma - Geographic Focus: China - Hepatocellular Carcinoma | China In-Depth | China

MARKET OUTLOOK The hepatocellular carcinoma (HCC) market in China is poised to experience substantial market growth. Availability of systemic targeted drugs is limited, with...

View Details

Hepatocellular Carcinoma - Unmet Need - Detailed, Expanded Analysis - Advanced Hepatocellular Carcinoma (US/EU5)

Hepatocellular carcinoma, the most common type of primary liver cancer, occurs as a results of chronic liver cirrhosis and has a five-year survival rate of only 18%. First-line advanced hepatocellu...

View Details

Hepatocellular Carcinoma | Disease Landscape and Forecast | G7 | 2019

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx), an angiogenesis inhibitor, was t...

View Details